30Oct
[Video] I Wish I Knew What I Know Now: Conversations with AGG on FDA Issues - Key Due Diligence Issues to Consider When Acquiring or Investing in Life Sciences Companies or Products
AGG is pleased to present the second episode in a podcast series titled, “I Wish I Know What I Know Now: Conversations with AGG on FDA Issues,” covering key due diligence issues to consider when acquiring or investing in life science companies or products. In this episode, AGG partner Alan G. Minsk and Brian A. Teras provides an overview of the diligence process, potential red flags, common mistakes, and other factors to consider during the due diligence process. Each month, we'll release a...
By:
Arnall Golden Gregory LLP
Related
The Federal Trade Commission (FTC) recently announced the revised transaction thresholds that trigge...
Read More >
Last week, the U.S. Citizenship and Immigration Services announced that it had completed pilot testi...
Read More >
Following the wider outbreak of the coronavirus (COVID-19) around the world, radical—and sometimes ...
Read More >
For at least two decades, Pennsylvania law has recognized an exemption from strict liability for pre...
Read More >
In the first-of-its-kind ruling last week, the Fifth Circuit held that the EEOC’s investigators and...
Read More >
The Singapore government has introduced additional control measures to minimize the risk of further ...
Read More >